Roche Holding AG will maintain a strategy of “targeted acquisitions” and isn’t seeking a mega- merger, Chief Executive Officer Severin Schwan said in comments that may rule out a bid for Abbott Laboratories’ prescription- drug spinoff.
“We’ve focused on smaller, bolt-on acquisitions,” Schwan said in an interview today in Frankfurt when asked whether an acquisition of a portion of Abbott’s business is attractive. “That’s how I see us continuing in our M&A strategy. We are not interested in mega-mergers. We are interested in very targeted acquisitions which complement our technologies and portfolios.
Entradas
No hay comentarios:
Publicar un comentario